

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent of  
**Francois CLERC, et. al.**

U.S. Patent No.: **7,041,668**

Issued: **May 9, 2006**

Title: **SUBSTITUTED BENZIMIDAZOLE  
COMPOUNDS AND THEIR USE FOR  
THE TREATMENT OF CANCER**

***Certificate of Transmission***

I hereby certify that this correspondence is being transmitted via EFS-Web to the Commissioner for Patents, Alexandria, VA 22313, on

July 25, 2006

Date of Transmission

Brian Pritchett Brian Pritchett

Signature

**REQUEST FOR CERTIFICATE OF CORRECTION**  
**UNDER 35 U.S.C. 254/255 and 37 C.F.R. 1.322/323**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Enclosed herewith is a required copy of the Certificate of Correction form for U.S. Patent No. 7,041,668 B2. The following errors in the patent, all of which are believed to be the fault of the USPTO, are of consequence and correction thereof is respectfully requested.

Column 1, Line 42 reads as:

“known substrate for cdk4 is the retinoblastoma gene product”

and should read as:

-- known substrate for CDK4 is the retinoblastoma gene product--, as appears in the Specification at page 1, line 30.


Column 1, Line 48 reads as:

“cycle progression, e.g. thymidine kinase, thymidylate syn-”


and should read as:

--cycle progression, e.g. thymidine kinase, thymidylate syn- --, as appears in the Specification at page 2, line 2.

Column 2, the structure beginning at Line 32 reads as:



and should read as:



--  
5.

--, as appears in the Specification at page 3, line

Column 3, Line 28 reads as:

“lmino sutstituent. In the preferred compounds of formula”

and should read as:

-- lmino substituent. In the preferred compounds of formula--, as appears in the Specification at page 4, line 24.

Column 160, Line 37 reads as:

“b 1-imidazolyl” and should read as:

--1-imidazolyl--, as appears in Applicants' amendment of claim 3 in their response of May 12, 2005.

Column 164, Line 33 reads as:

“cyclopentylamino and R<sub>2</sub> is aryl a aralkyl optionally substi-”

and should read as:

--cyclopentylamino and R<sub>2</sub> is aryl or aralkyl optionally substi- --, as appears in Applicants' amendment of claim 15 in their response of May 12, 2005.

**REMARKS**

Applicants respectfully submit that the above errors occurred while printing the US Patent No. 7,041,668 B2 not attributable to any of the errors by the Applicants. In support of this assertion, Applicants have provided above the same passages as they appeared in the Specification as filed as well as the response filed by the Applicants on May 12, 2005.

In view of the foregoing remarks, issuance of a Certificate of Correction is respectfully requested. Applicants believe that there are no fees due for this request, however, if the Commissioner deems that fees are due to this request, please charge such required fees to Account No. **18-1982**, for sanofi-aventis Inc. LLC, Bridgewater, NJ. Please credit any overpayment to Deposit Account No. **18-1982**.

Respectfully submitted,

July 25, 2006



Balaram Gupta, Reg. No. 40,009  
Attorney/Agent for Applicant

sanofi-aventis Inc. LLC  
U.S. Patent Operations  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-3364  
Telefax (908) 231-2626  
sanofi-aventis Docket No. ST01027 US CNT

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

PATENT NO. : 7,041,668 B2

DATED : May 9, 2006

INVENTOR(S) : Francois CLERC, et. al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 1, Line 42 reads as:

"known substrate for cdk4 is the retinoblastoma gene product"

and should read as:

-- known substrate for CDK4 is the retinoblastoma gene product--


Column 1, Line 48 reads as:

"cycle progression, e.g. thymidine kinase, thymidylate syn-"


and should read as:

--cycle progression, e.g. thymidine kinase, thymidylate syn- --

Column 2, the structure beginning at Line 32 reads as:



and should read as:



Mailing Address of Sender:

Patent No. 7,041,668 B2

Balaram Gupta, U.S. Patent Operations  
sanofi-aventis Inc. LLC  
Route #202-206  
P. O. Box 6800  
Bridgewater, New Jersey 08807-0800

⇒ 1 of 2

Certificate of Correction (PTO Form 1050) - Amended

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

PATENT NO. : 7,041,668 B2

DATED : May 9, 2006

INVENTOR(S) : Francois CLERC, et. al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 3, Line 28 reads as:

"lamino sutstituent. In the preferred compounds of formula"

and should read as:

-- lamino substituent. In the preferred compounds of formula--

Column 160, Line 37 reads as:

"b 1-imidazolyl" and should read as:

--1-imidazolyl--

Column 164, Line 33 reads as:

"cyclopentylamino and R<sub>2</sub> is aryl a aralkyl optionally substi--"

and should read as:

--cyclopentylamino and R<sub>2</sub> is aryl or aralkyl optionally substi- --

Mailing Address of Sender:

Patent No. 7,041,668 B2

**Balaram Gupta**, U.S. Patent Operations  
sanofi-aventis Inc. LLC  
Route #202-206  
P. O. Box 6800  
Bridgewater, New Jersey 08807-0800

⇒ 2 of 2

Certificate of Correction (PTO Form 1050) - Amended